Epizyme, Inc. (EPZM) EPS Estimated At $-0.59

October 14, 2018 - By Nellie Frank

Epizyme, Inc. (NASDAQ:EPZM) LogoInvestors sentiment decreased to 1.4 in Q2 2018. Its down 0.10, from 1.5 in 2018Q1. It turned negative, as 16 investors sold Epizyme, Inc. shares while 24 reduced holdings. 17 funds opened positions while 39 raised stakes. 57.28 million shares or 0.28% less from 57.44 million shares in 2018Q1 were reported.
Tiaa Cref Ltd Limited Liability Company has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Prtnrs Ltd Com owns 0.08% invested in Epizyme, Inc. (NASDAQ:EPZM) for 156,700 shares. Citadel Advsrs Ltd Limited Liability Company holds 810,119 shares. Credit Suisse Ag reported 0% stake. Schwab Charles Inv stated it has 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). University Of Notre Dame Du Lac holds 0.46% in Epizyme, Inc. (NASDAQ:EPZM) or 173,982 shares. Ameriprise Fincl Inc accumulated 0% or 10,980 shares. Commercial Bank Of Montreal Can invested in 372 shares or 0% of the stock. Teacher Retirement Sys Of Texas accumulated 10,529 shares. National Bank Of Mellon reported 225,764 shares. Tekla Ltd Llc reported 485,325 shares. Hbk Investments L P accumulated 64,760 shares. Moreover, Daiwa Secs Inc has 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 383 shares. Millennium Llc holds 0% or 69,979 shares in its portfolio. Art Ltd Liability Co accumulated 0.04% or 66,924 shares.

Analysts expect Epizyme, Inc. (NASDAQ:EPZM) to report $-0.59 EPS on November, 7.They anticipate $0.04 EPS change or 6.35 % from last quarter’s $-0.63 EPS. After having $-0.42 EPS previously, Epizyme, Inc.’s analysts see 40.48 % EPS growth. The stock increased 0.97% or $0.09 during the last trading session, reaching $9.34. About 776,202 shares traded or 51.81% up from the average. Epizyme, Inc. (NASDAQ:EPZM) has declined 42.98% since October 14, 2017 and is downtrending. It has underperformed by 58.60% the S&P500.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Among 5 analysts covering Epizyme (NASDAQ:EPZM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Epizyme had 7 analyst reports since April 23, 2018 according to SRatingsIntel. The firm has “Buy” rating by Leerink Swann given on Tuesday, April 24. SunTrust maintained it with “Buy” rating and $2000 target in Monday, April 23 report. Roth Capital maintained the stock with “Buy” rating in Tuesday, April 24 report. On Friday, September 7 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The rating was downgraded by Leerink Swann on Tuesday, July 3 to “Market Perform”. The firm earned “Outperform” rating on Tuesday, April 24 by Wedbush.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $727.35 million. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Businesswire.com which released: “Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase …” on October 05, 2018, also Seekingalpha.com with their article: “Epizyme readies stock offering; shares down 4% after hours” published on October 02, 2018, Seekingalpha.com published: “Key events next week – healthcare” on October 12, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Seekingalpha.com and their article: “Epizyme prices equity offering, shares down 7.3% premarket” published on October 03, 2018 as well as Seekingalpha.com‘s news article titled: “Epizyme: An Updated Investment Thesis” with publication date: September 26, 2018.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: